Source / episode info
- **Episode:**70
- **Title:**Divine Intervention Episode 70 – Oncology Pharm For The USMLEs Part 1
- **Published:**2019-01-09
- Source:Episode page
One-liner
This episode covers antimetabolites (Methotrexate and 5-Fluorouracil), pyrimidine/purine analogs (Cytarabine, Thiopurines), and anti-cancer antibiotics (Doxorubicin, Bleomycin), emphasizing their distinct mechanisms of DNA synthesis inhibition and associated toxicities.
High-yield summary
- Folate Antagonists: Methotrexate inhibits Dihydrofolate Reductase (DHFR), preventing the regeneration of tetrahydrofolate ({THF}) necessary for converting deoxyuridine monophosphate ({dUMP}) to {deoxythymidine monophosphate} ({dTMP}).
- Pyrimidine Analogs: 5-Fluorouracil (5-FU) is metabolized to 5-FdUMP, which irreversibly inhibits Thymidylate Synthase (TS), blocking the conversion of {dUMP} to {dTMP}.
- Rescue Agents Trap: Leucovorin ({THF} analog) reverses Methotrexate toxicity by providing excess folate cofactors but increases 5-FU toxicity because it fuels the TS reaction.
- Anti-cancer Antibiotics: Doxorubicin (anthracycline) generates free radicals via the Fenton reaction, causing dose-dependent cardiotoxicity; this is mitigated by Dexrazoxane.
- Cell Cycle Specificity: Bleomycin is unique among anti-cancer agents because it specifically targets and inhibits DNA synthesis during the {G}_2 phase of the cell cycle.
- Purine Salvage Pathway: Defects in HGPRT (Hypoxanthine Guanine Phosphoribosyltransferase) lead to Lesch-Nyhan syndrome, highlighting the importance of purine metabolism pathways.
Learning objectives
- Differentiate between the mechanisms of action and clinical uses of Methotrexate (DHFR inhibitor) and 5-Fluorouracil (TS inhibitor).
- Identify the appropriate rescue agent for MTX toxicity versus 5-FU toxicity, recognizing the critical role of Leucovorin.
- Recognize the mechanism and antidote/preventative measure for anthracycline cardiotoxicity (Doxorubicin -> Dexrazoxane).
- Understand the metabolic consequences of purine salvage pathway defects, specifically in Lesch-Nyhan syndrome (\text{HGPRT}).
- Correlate specific anti-cancer antibiotics with their unique cell cycle phase targets or toxicities (e.g., Bleomycin in \text{G}_2).